SCHEMBL19183641

SCHEMBL19183641

CC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(C)cc2)[nH]1)C(C)C

nearest known ligand 0.75

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.75
CYP2C9 P11712 5/20 0.75
NR1I2 O75469 2/20 0.75
KCNH2 Q12809 2/20 0.75
ABCB11 O95342 1/20 0.75
OPRK1 P41145 1/20 0.75
CYP1A2 P05177 3/20 0.67
CYP2D6 P10635 2/20 0.66
PRCP P42785 4/20 0.55
HCRTR1 O43613 1/20 0.49
HCRTR2 O43614 1/20 0.49
OPRM1 P35372 2/20 0.47
OPRD1 P41143 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746726 0.95 CYP3A4 (0.82) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL1746728 0.95 CYP3A4 (0.82) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL12175155 0.95 CYP3A4 (0.82) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL15500054 0.91 CYP3A4 (0.91) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL16479743 0.91 CYP3A4 (0.91) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL12567635 0.91 CYP3A4 (0.91) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL12567578 0.91 CYP3A4 (0.91) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL13929970 0.90 CYP3A4 (0.93) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL13306512 0.90 CYP3A4 (0.93) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL18475464 0.90 CYP3A4 (0.93) CYP3A4CYP2C9NR1I2KCNH2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9775831-B2 Combinations comprising biphenyl derivatives for use in the treatment of HCV BRISTOL-MYERS SQUIBB COMPANY (US) 2017-10-03 US disclosed
US-9717712-B2 Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-01 US disclosed